Compare TTC & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TTC | ABVX |
|---|---|---|
| Founded | 1914 | 2013 |
| Country | United States | France |
| Employees | N/A | 67 |
| Industry | Tools/Hardware | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 9.7B |
| IPO Year | 1994 | N/A |
| Metric | TTC | ABVX |
|---|---|---|
| Price | $89.82 | $73.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 13 |
| Target Price | $104.00 | ★ $131.31 |
| AVG Volume (30 Days) | 658.4K | ★ 966.2K |
| Earning Date | 06-04-2026 | 03-23-2026 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $2,618,650,000.00 | N/A |
| Revenue This Year | $6.13 | $52.14 |
| Revenue Next Year | $4.45 | $4,132.27 |
| P/E Ratio | $130.41 | ★ N/A |
| Revenue Growth | ★ 4.53 | N/A |
| 52 Week Low | $67.45 | $5.75 |
| 52 Week High | $105.19 | $148.83 |
| Indicator | TTC | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 39.02 | 23.77 |
| Support Level | $86.95 | $67.15 |
| Resistance Level | $97.32 | $130.98 |
| Average True Range (ATR) | 2.50 | 6.25 |
| MACD | -0.00 | -2.49 |
| Stochastic Oscillator | 34.62 | 6.25 |
The Toro Co designs, manufactures, markets, and sells professional turf maintenance equipment and services; turf and agricultural irrigation systems; landscaping equipment and lighting products; snow and ice management equipment; construction equipment; and residential yard and snow thrower products. The company operates through Professional and Residential segments, with the Professional segment serving commercial, agricultural, and construction customers and generating the majority of revenue, while the Residential segment focuses on homeowners. Its products are sold through distributors, dealers, retailers, rental centers, and direct channels, with the United States as its primary revenue-generating market.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.